In addition, in NSCLC patients harboring ALK fusion, nuclear YAP is highly expressed in ALK-TKI-resistant samples, and high expression levels of YAP are related to weak response to ALK-TKIs [94]. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.